Hantz Financial Services, Inc. Neurocrine Biosciences Inc Transaction History

Hantz Financial Services, Inc.

  • $6.6 Billion
  • Q3 2025

A detailed history of Hantz Financial Services, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 2,005 shares of NBIX stock, worth $290,444. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,005
Previous 1,312 52.82%
Holding current value
$290,444
Previous $165,000 70.3%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025
BUY
$123.98 - $146.67 $85,918 - $101,642
693 Added 52.82%
2,005 $281,000
Q2 2025

Aug 04, 2025
BUY
$87.54 - $128.18 $59,789 - $87,546
683 Added 108.59%
1,312 $165,000
Q1 2025

May 12, 2025
SELL
$107.22 - $153.29 $5,253 - $7,511
-49 Reduced 7.23%
629 $70,000
Q4 2024

Jan 23, 2025
SELL
$111.62 - $139.44 $27,793 - $34,720
-249 Reduced 26.86%
678 $93,000
Q2 2024

Jul 30, 2024
BUY
$130.86 - $143.19 $121,307 - $132,737
927 New
927 $128,000
Q1 2024

Aug 06, 2024
SELL
$130.4 - $143.74 $17,212 - $18,973
-132 Reduced 12.29%
942 $130,000
Q4 2023

Aug 06, 2024
SELL
$106.07 - $132.76 $10,819 - $13,541
-102 Reduced 8.67%
1,074 $142,000
Q3 2023

Aug 06, 2024
SELL
$94.02 - $117.1 $30,180 - $37,589
-321 Reduced 21.44%
1,176 $132,000
Q2 2023

Aug 06, 2024
SELL
$89.53 - $104.87 $9.51 Million - $11.1 Million
-106,276 Reduced 98.61%
1,497 $141,000
Q1 2023

Aug 06, 2024
SELL
$94.11 - $123.02 $188,502 - $246,409
-2,003 Reduced 1.82%
107,773 $10.9 Million
Q4 2022

Aug 06, 2024
SELL
$106.72 - $127.06 $4.99 Million - $5.94 Million
-46,783 Reduced 29.88%
109,776 $13.1 Million
Q3 2022

Aug 06, 2024
BUY
$92.03 - $107.81 $128,749 - $150,826
1,399 Added 0.9%
156,559 $16.6 Million
Q2 2022

Aug 06, 2024
BUY
$75.79 - $100.07 $304,827 - $402,481
4,022 Added 2.66%
155,160 $15.1 Million
Q1 2022

Aug 06, 2024
BUY
$72.45 - $94.81 $6.48 Million - $8.48 Million
89,462 Added 145.05%
151,138 $14.2 Million
Q4 2021

Aug 06, 2024
BUY
$79.65 - $106.22 $448,668 - $598,337
5,633 Added 10.05%
61,676 $5.25 Million
Q3 2021

Aug 06, 2024
BUY
$86.18 - $99.03 $648,590 - $745,299
7,526 Added 15.51%
56,043 $5.38 Million
Q2 2021

Aug 06, 2024
BUY
$89.43 - $102.27 $144,429 - $165,166
1,615 Added 3.44%
48,517 $4.72 Million
Q1 2021

Aug 06, 2024
BUY
$87.57 - $119.4 $4.03 Million - $5.49 Million
45,975 Added 4959.55%
46,902 $4.56 Million
Q4 2020

Aug 06, 2024
BUY
$86.91 - $108.33 $254,646 - $317,406
2,930 Added 6.83%
45,800 $4.39 Million
Q3 2020

Aug 06, 2024
BUY
$96.16 - $135.15 $4.03 Million - $5.67 Million
41,943 Added 4524.6%
42,870 $4.12 Million

Others Institutions Holding NBIX

# of Institutions
741
Shares Held
102M
Call Options Held
230K
Put Options Held
477K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email